Cyclacel Prescription drugs Declares That Kenneth M.
Pharmaceuticals

Cyclacel Prescription drugs Declares That Kenneth M.

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) — Cyclacel Prescription drugs, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Firm”), a biopharmaceutical firm growing modern medicines based mostly on most cancers cell biology, as we speak introduced the election of Kenneth M. Ferguson, Ph.D., to its Board of Administrators. Dr. Ferguson was elected by and can symbolize the 6% Convertible Exchangeable Most popular stockholders.

“We’re very happy to welcome Ken to our Board of Administrators,” mentioned Christopher Henney, Ph.D., DSc, Chairman of the Board of Cyclacel. “As a extremely achieved scientist with intensive drug growth expertise, he’ll present important experience and perception to assist information our ongoing scientific growth packages and advance our firm’s pipeline.”

“Cyclacel has made large progress in growing fadraciclib and CYC140, novel and extremely differentiated most cancers therapies with aggressive product profiles to deal with a broad vary of strong tumors and blood cancers,” mentioned Dr. Ferguson. “With fadraciclib, the main CDK2/9 inhibitor, and CYC140 advancing via Part 1/2 scientific research, I sit up for contributing to Cyclacel’s mission in offering tolerated, oral therapies to sufferers affected by most cancers.”

Dr. Ferguson’s skilled expertise consists of over 30 years of scientific and drug growth expertise within the biopharmaceutical business. At present, he serves as an Working Accomplice at Accelerator Life Science Companions. Beforehand, he was Chief Scientific Officer of EMulate Therapeutics, the place he was chargeable for the investigation of magnetic discipline results on cell processes to allow novel therapeutic methods. He beforehand spent seven years with Omeros Corp, the place he final held the place of Chief Growth Officer. Earlier in his profession, he spent over seventeen years with ICOS Corp, culminating in his appointment as President in 2007 the place he oversaw the mixing of ICOS into Eli Lilly & Co. Previous to his appointment as President, he served in a number of roles inside ICOS, together with as Vice President, Therapeutic Growth, in addition to Chief Working Officer, Chief Scientific Officer, and Member of the Board of Managers of Lilly ICOS LLC the place he chargeable for strategic administration. He has authored or co-authored 26 scientific papers and eight issued patents.

Dr. Ferguson earned a B.S. in Organic Sciences from Cornell College and acquired his Ph.D. in Pharmacology from the College of Texas Well being Science Middle. He accomplished his post-doctoral examine on the Chilly Spring Harbor Laboratory.

About Cyclacel Prescription drugs, Inc.
Cyclacel is a clinical-stage, biopharmaceutical firm growing modern most cancers medicines based mostly on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in sufferers with each strong tumors and hematological malignancies. Cyclacel’s technique is to construct a diversified biopharmaceutical enterprise based mostly on a pipeline of novel drug candidates addressing oncology and hematology indications. For extra data, please go to www.cyclacel.com. 

Ahead-looking Statements
This information launch comprises sure forward-looking statements that contain dangers and uncertainties that would trigger precise outcomes to be materially totally different from historic outcomes or from any future outcomes expressed or implied by such forward-looking statements. Such forward-looking statements embody statements relating to, amongst different issues, the efficacy, security and meant utilization of Cyclacel’s product candidates, the conduct and outcomes of future scientific trials, plans relating to regulatory filings, future analysis and scientific trials and plans relating to partnering actions. Elements that will trigger precise outcomes to vary materially embody the chance that product candidates that appeared promising in early analysis and scientific trials don’t show security and/or efficacy in larger-scale or later scientific trials, trials might have issue enrolling, Cyclacel might not acquire approval to market its product candidates, the dangers related to reliance on exterior financing to fulfill capital necessities, the potential results of the COVID-19 pandemic, and the dangers related to reliance on collaborative companions for additional scientific trials, growth and commercialization of product candidates. You’re urged to think about statements that embody the phrases “might,” “will,” “would,” “may,” “ought to,” “believes,” “estimates,” “tasks,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “purpose,” or the detrimental of these phrases or different comparable phrases to be unsure and forward-looking. For an extra checklist and outline of the dangers and uncertainties the Firm faces, please discuss with our most up-to-date Annual Report on Kind 10-Okay and different periodic and different filings we file with the Securities and Change Fee and can be found at www.sec.gov. Such forward-looking statements are present solely as of the date they’re made, and we assume no obligation to replace any forward-looking statements, whether or not because of new data, future occasions or in any other case.

Contacts

Firm: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com 

Investor Relations: Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com